NCT06755801Not yet recruitingPhase 3
Nebivolol ANOCA Treatment Randomized Trial
Microvascular Obstruction Treatment and Outcomes Randomized Study.
Source: ClinicalTrials.gov · Last updated 1 Jan 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
To determine the effectiveness of the beta-blocker nebivolol in controlling symptoms and improving the quality of life in patients with angina and coronary microvascular dysfunction.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- First submitted
- 6 Dec 2024
- Start date
- 1 Apr 2025
- Primary completion date
- 30 Mar 2026
- Lead sponsor
- Spanish Society of Cardiology
- Diseases
- Coronary artery disease
- NCT number
- NCT06755801
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 150
- From 1 Apr 2025 to the primary completion date, 30 Mar 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Allergy or contraindication to the use of beta-blockers.
- History of surgical revascularization.
- Presence of cardiomyopathy or congenital cardiac anomaly.
Lab values
- Ventricular dysfunction (LVEF \< 45%).
- Severe renal insufficiency (eGFR \< 30 ml/min).
- Liver failure (history of cirrhosis or transaminase elevation \> 3 times the upper limit of normal).
Other
- Indication for beta-blocker treatment due to another pathology.
- Percutaneous coronary revascularization in the last 6 months.
- First-degree atrioventricular block or bifascicular block.
- Presence of hemodynamically significant valvulopathy.
- Pregnant or lactating women.
Who the study is looking for
- Age 18 years or older.
- Presence of stable angina symptoms, defined as compatible symptoms occurring at least once weekly in the last three months.
- Absence of functionally significant epicardial coronary artery disease (FFR \> 0.80).
- Microvascular functional study showing CFR\< 2,0 and/or IMR ≥ 25.
Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.